“Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials” (2024) SKIN The Journal of Cutaneous Medicine, 8(4), p. s406. doi:10.25251/skin.8.supp.406.